All In Biotech

Drug Trial Radar · NCT07175493

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

Nov 18, 2027

Study completion Nov 18, 2028

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Conditions

  • Autoimmune Cytopenia
  • Immune Thrombocytopenia (ITP)
  • Autoimmune Hemolytic Anemia
  • Evans Syndrome

Interventions

  • CM336 InjectionBiological

    subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 52 weeks
  2. Efficacy of CM336Time frame: 8 weeks
  3. Proportion of ITP subjects with a platelet count ≥ 50 × 10^9/L at least twice during the visit.Time frame: up to 52 weeks.
  4. Proportion of AIHA subjects with at least one instance of hemoglobin ≥ 100 g/L, and an increase ≥ 20 g/L compared to the baseline level.Time frame: up to 52 weeks.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • Blood Disease Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.